Your browser doesn't support javascript.
A human coronavirus evolves antigenically to escape antibody immunity.
Eguia, Rachel T; Crawford, Katharine H D; Stevens-Ayers, Terry; Kelnhofer-Millevolte, Laurel; Greninger, Alexander L; Englund, Janet A; Boeckh, Michael J; Bloom, Jesse D.
  • Eguia RT; Basic Sciences and Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Crawford KHD; Basic Sciences and Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Stevens-Ayers T; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
  • Kelnhofer-Millevolte L; Medical Scientist Training Program, University of Washington, Seattle, Washington, United States of America.
  • Greninger AL; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Englund JA; Medical Scientist Training Program, University of Washington, Seattle, Washington, United States of America.
  • Boeckh MJ; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Bloom JD; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America.
PLoS Pathog ; 17(4): e1009453, 2021 04.
Article in English | MEDLINE | ID: covidwho-1172889
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
There is intense interest in antibody immunity to coronaviruses. However, it is unknown if coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this question by characterizing the historical evolution of human coronavirus 229E. We identify human sera from the 1980s and 1990s that have neutralizing titers against contemporaneous 229E that are comparable to the anti-SARS-CoV-2 titers induced by SARS-CoV-2 infection or vaccination. We test these sera against 229E strains isolated after sera collection, and find that neutralizing titers are lower against these "future" viruses. In some cases, sera that neutralize contemporaneous 229E viral strains with titers >1100 do not detectably neutralize strains isolated 8-17 years later. The decreased neutralization of "future" viruses is due to antigenic evolution of the viral spike, especially in the receptor-binding domain. If these results extrapolate to other coronaviruses, then it may be advisable to periodically update SARS-CoV-2 vaccines.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus 229E, Human / Antibodies, Neutralizing / Immune Evasion / Antibodies, Viral Topics: Vaccines Limits: Humans Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: Journal.ppat.1009453

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus 229E, Human / Antibodies, Neutralizing / Immune Evasion / Antibodies, Viral Topics: Vaccines Limits: Humans Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: Journal.ppat.1009453